Public Sector Pension Investment Board Has $9.03 Million Position in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA)

Public Sector Pension Investment Board boosted its stake in shares of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA - Free Report) by 7.0% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 587,167 shares of the company's stock after acquiring an additional 38,400 shares during the quarter. Public Sector Pension Investment Board owned 0.05% of Teva Pharmaceutical Industries worth $9,025,000 as of its most recent SEC filing.

Several other hedge funds have also recently bought and sold shares of TEVA. Ion Asset Management Ltd. grew its holdings in shares of Teva Pharmaceutical Industries by 1.1% during the fourth quarter. Ion Asset Management Ltd. now owns 36,650,000 shares of the company's stock worth $807,766,000 after purchasing an additional 409,778 shares during the last quarter. Migdal Insurance & Financial Holdings Ltd. grew its holdings in shares of Teva Pharmaceutical Industries by 1.2% during the first quarter. Migdal Insurance & Financial Holdings Ltd. now owns 26,335,422 shares of the company's stock worth $404,775,000 after purchasing an additional 300,000 shares during the last quarter. Harel Insurance Investments & Financial Services Ltd. boosted its holdings in Teva Pharmaceutical Industries by 197,885.2% in the first quarter. Harel Insurance Investments & Financial Services Ltd. now owns 22,055,547 shares of the company's stock valued at $338,989,000 after acquiring an additional 22,044,407 shares during the last quarter. Duquesne Family Office LLC boosted its holdings in Teva Pharmaceutical Industries by 530.1% in the fourth quarter. Duquesne Family Office LLC now owns 8,997,400 shares of the company's stock valued at $198,303,000 after acquiring an additional 7,569,450 shares during the last quarter. Finally, Janus Henderson Group PLC boosted its holdings in Teva Pharmaceutical Industries by 40.6% in the fourth quarter. Janus Henderson Group PLC now owns 6,737,625 shares of the company's stock valued at $148,497,000 after acquiring an additional 1,945,688 shares during the last quarter. 54.05% of the stock is currently owned by institutional investors and hedge funds.

Teva Pharmaceutical Industries Trading Up 2.0%

NYSE TEVA opened at $17.55 on Friday. The firm has a market cap of $20.13 billion, a P/E ratio of -109.71, a P/E/G ratio of 1.02 and a beta of 0.62. The company has a debt-to-equity ratio of 2.45, a current ratio of 1.06 and a quick ratio of 0.77. The stock's 50-day moving average is $16.69 and its 200-day moving average is $16.29. Teva Pharmaceutical Industries Ltd. has a one year low of $12.47 and a one year high of $22.80.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last announced its earnings results on Wednesday, July 30th. The company reported $0.66 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.64 by $0.02. Teva Pharmaceutical Industries had a positive return on equity of 46.10% and a negative net margin of 0.95%. The business had revenue of $4.18 billion for the quarter, compared to analyst estimates of $4.34 billion. During the same quarter last year, the firm earned $0.61 EPS. Teva Pharmaceutical Industries's revenue for the quarter was up .3% compared to the same quarter last year. Sell-side analysts anticipate that Teva Pharmaceutical Industries Ltd. will post 2.5 earnings per share for the current fiscal year.

Insider Activity at Teva Pharmaceutical Industries

In other news, insider Eric A. Hughes sold 52,742 shares of the stock in a transaction that occurred on Friday, August 1st. The stock was sold at an average price of $15.16, for a total value of $799,568.72. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Matthew Shields sold 6,206 shares of the stock in a transaction that occurred on Tuesday, June 3rd. The shares were sold at an average price of $17.02, for a total value of $105,626.12. Following the completion of the sale, the executive vice president directly owned 9,989 shares of the company's stock, valued at approximately $170,012.78. The trade was a 38.32% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 65,001 shares of company stock valued at $996,958. 0.49% of the stock is owned by insiders.

Analyst Ratings Changes

Several equities analysts recently issued reports on the company. Truist Financial assumed coverage on Teva Pharmaceutical Industries in a report on Wednesday, May 28th. They issued a "buy" rating and a $25.00 price target on the stock. UBS Group decreased their price target on Teva Pharmaceutical Industries from $24.00 to $23.00 and set a "buy" rating on the stock in a report on Thursday, June 26th. The Goldman Sachs Group assumed coverage on Teva Pharmaceutical Industries in a report on Friday, June 6th. They issued a "buy" rating and a $24.00 price target on the stock. Hsbc Global Res upgraded Teva Pharmaceutical Industries to a "strong-buy" rating in a report on Monday, April 28th. Finally, Wall Street Zen upgraded Teva Pharmaceutical Industries from a "hold" rating to a "buy" rating in a report on Saturday, July 26th. Seven equities research analysts have rated the stock with a buy rating and two have given a strong buy rating to the stock. According to MarketBeat.com, Teva Pharmaceutical Industries presently has a consensus rating of "Buy" and an average price target of $24.71.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.

Want to see what other hedge funds are holding TEVA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Teva Pharmaceutical Industries Ltd. (NYSE:TEVA - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.